Sign in

CIK 0001069530

  • Non-accelerated filer
  • Smaller reporting company

FILANA THERAPEUTICS, INC.

Sign in to watch
Ticker
FLNA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
911911336
Phone
+1 512-501-2444
Business address
6801 N CAPITAL OF TEXAS HIGHWAY, BUILDING 1; SUITE 300, AUSTIN, TX, 78731
Former names
CASSAVA SCIENCES INC, PAIN THERAPEUTICS INC
  1. 3 Insider Initial Statement of Ownership
  2. 4 Open-market sale President and CEO sold 50,000 shares at an average $10.19 ($509,500)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Derivatives Options or other derivatives
  5. 4 Open-market sale President and CEO sold 50,000 shares at an average $10.26 ($512,750)
  6. 4 Open-market buy Vice President and CFO bought 1,026 shares at $6.50 ($6,669)
  7. 4 Open-market buy Chief Operating & Med. Officer bought 193 shares at $6.50 ($1,255)
  8. 4 Open-market sale President and CEO sold 50,000 shares at an average $10.91 ($545,250)
  9. 4 Open-market sale President and CEO sold 50,000 shares at an average $9.70 ($484,750)
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Open-market sale President and CEO sold 50,000 shares at an average $9.54 ($476,750)
  14. 4 Open-market buy 10% owner bought 17,000 shares at an average $8.36 ($142,150)
  15. 4 Open-market buy 10% owner bought 15,000 shares at an average $8.50 ($127,550)
  16. 4 Open-market buy 10% owner bought 100 shares at $8.24 ($824)
  17. 4 Open-market sale President and CEO sold 50,000 shares at an average $8.45 ($422,250)
  18. 4 Open-market buy 10% owner bought 10,075 shares at $8.34 ($84,026)
  19. 4 Open-market buy 10% owner bought 7,277 shares at $8.41 ($61,200)
  20. 4 Open-market buy 10% owner bought 3,390 shares at $8.27 ($28,035)

Page 21 of 30 · 591 filings